Slow-release prepn. contg. alpha-lipoic acid or its derivatives, and preparing method therefor

A sustained-release preparation, lipoic acid technology, applied in the field of biomedicine, can solve problems affecting biological activity and achieve the effect of prolonged and sustained release

Inactive Publication Date: 2006-11-29
ZHUJIANG HOSPITAL SOUTHERN MEDICAL UNIV
View PDF0 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] α-lipoic acid or its derivatives are thermally unstable compounds. Since the current conventional tablets are melt-extruded by hot cutting method, the temperature is generally 50-200°C, which may thermally decompose α-lipoic acid and affect its biological activity. At present, there is no report on the development of sustained-release preparations of α-lipoic acid or its derivatives that are practical and can maintain the drug effect for a long time

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Slow-release prepn. contg. alpha-lipoic acid or its derivatives, and preparing method therefor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045]The prescription of the double-layer sustained-release tablet whose main ingredient is R-(+)-α-lipoic acid is:

[0046] Sustained-release drug raw material components and content are:

[0047] R-(+)-alpha-lipoic acid 200 mg

[0048] Lactose 10mg

[0049] Hydroxypropyl Methyl Cellulose 125 mg

[0050] Ethylcellulose 20 mg

[0051] 1.5% hydroxypropyl methylcellulose solution 40 mg

[0052] Talc 5 mg

[0053] Magnesium stearate 2mg

[0054] The components and content of the raw material of the long-release drug are:

[0055] R-(+)-alpha-lipoic acid 100 mg

[0056] Starch 10 mg

[0057] 6% polyvinylpyrrolidone solution 10 mg

[0058] Talc 2 mg

[0059] Magnesium stearate 2mg

[0060] The film coat composition and content of this double-layer sustained-release tablet are:

[0061] Hydroxypropyl Methyl Cellulose 4 mg

[0062] Macrogol 400 6 mg

[0063] Titanium dioxide 0.5 mg

[0064] Talc 1mg

[0065] 80ml food grade ethanol

[0066] water 20ml

[0067] The ...

Embodiment 2

[0079] The main ingredient is S-(-)-α-lipoic acid The prescription of the double-layer sustained-release tablet is:

[0080] Sustained-release drug raw material components and content are:

[0081] S-(-)-alpha-lipoic acid 250 mg

[0082] Lactose 10mg

[0083] Hydroxypropyl Methyl Cellulose 125 mg

[0084] Ethylcellulose 20 mg

[0085] 1.5% hydroxypropyl methylcellulose solution 40 mg

[0086] Talc 5mg

[0087] Magnesium stearate 2mg

[0088] The components and content of the raw material of the long-release drug are:

[0089] S-(-)-alpha-lipoic acid 50 mg

[0090] Starch 10 mg

[0091] 6% polyvinylpyrrolidone solution 10 mg

[0092] Talc 2 mg

[0093] Magnesium stearate 2mg

[0094] The film coat composition and content of this double-layer sustained-release tablet are:

[0095] Hydroxypropyl Methyl Cellulose 4mg

[0096] Macrogol 400 6 mg

[0097] Titanium dioxide 0.5 mg

[0098] Talc 1mg

[0099] 80ml food grade ethanol

[0100] water 20ml

[0101] The prep...

Embodiment 3

[0113] The prescription of sustained-release tablets whose main drug is a mixture of R-(+)-α-lipoic acid and S-(-)-α-lipoic acid is:

[0114] Blend of R-(+)-alpha-lipoic acid and S-(-)-alpha-lipoic acid 300mg

[0115] Lactose 10mg

[0116]Hydroxypropyl Methyl Cellulose 125 mg

[0117] Ethylcellulose 20 mg

[0118] 1.5% hydroxypropyl methylcellulose solution 40 mg

[0119] Talc 5mg

[0120] Magnesium stearate 2mg

[0121] The film coat component and content of this layer sustained-release tablet are:

[0122] Hydroxypropyl Methyl Cellulose 4mg

[0123] Macrogol 400 6 mg

[0124] Titanium dioxide 0.5 mg

[0125] Talc 1mg

[0126] 80ml food grade ethanol

[0127] water 20ml

[0128] The preparation process of this slow-release tablet is as follows:

[0129] Mixture of R-(+)-α-lipoic acid and S-(-)-α-lipoic acid, starch, hydroxypropylmethylcellulose, ethylcellulose, microcrystalline cellulose, sodium starch glycolate According to the composition and content of the pre...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A slow-release tablet of alpha-thioctic acid or its derivative used as medicine, food additive, or cosmetic has a single slow-release layer made of hydroxypropyl methylcellulose or one slow-release layer plus one ordinary-release layer for quickly releasing the alpha-thioctic acid or its derivative. Its preparing process is also disclosed.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and relates to a sustained-release preparation of alpha-lipoic acid or a derivative thereof and a preparation method thereof. Background technique [0002] α-lipoic acid (LA) is known as the "universal antioxidant" and is the most effective known natural antioxidant. Its chemical name is 1,2-dithiolane- 3-pentanoic acid. In animal and plant tissues, LA is usually covalently bound to the ε-amino group of lysine residues in protein molecules, and exists in the form of amide bonds. The plant with the highest LA content is spinach, followed by tomato and cabbage; LA content is the highest in liver and kidney tissues in animals. LA is a cofactor for pyruvate dehydrogenase. It is a metabolic antioxidant that can be converted into reduced dihydrolipoic acid (DHLA) in the body, with the molecular formula C 8 h 14 S 2 o 2 , the molecular weight is 206.33. [0003] In recent years, the importan...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/22A61K31/385A61K47/38A61K47/26A61K47/02A61P39/06A61P3/10A61P1/16A61P29/00A23L1/30
Inventor 季爱民王秉钧姚育法张守尧杨月莲李晓东张忠义
Owner ZHUJIANG HOSPITAL SOUTHERN MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap